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Abstract
Background: Decisions on palliative chemotherapy (CT) for locally advanced or metastatic gastric cancer (mGC)
require trade-offs between potential benefits and risks for patients. Healthcare providers and payers agree that
patient-preferences should be considered. We conducted a choice-based conjoint (CBC) analysis study in pre-
treated patients from Germany with mGC or locally advanced or metastatic adenocarcinoma of the
gastroesophageal junction (mGEJ-Ca), to evaluate their preferences when hypothetically selecting a CT regimen.
Methods: German oncologists and gastroenterologists were contacted to identify patients with mGC or mGEJ-Ca
who had completed ≥2 cycles of palliative CT in first or later lines of therapy (CT ongoing or complete). The
primary objective was to quantify patient preferences for palliative CT by CBC analysis. Six in-depth qualitative
interviews identified 3 attributes: treatment tolerability, quality of life in terms of ability of self-care, and additional
survival benefit. The CBC matrix was constructed with 4 factor levels per attribute and each participant was
presented with 15 different iterations of these levels. A minimum of 50 participants was needed. Consenting
patients completed the CBC survey, choosing systematically among profiles. CBC models were estimated by
multinomial logistic regression (MLR) and hierarchical Bayesian (HB) analysis. Estimates of importance for each
attribute and factor-level were calculated.
Results: Fifty-five patients participated in the CBC survey (78.2% male, median age 63 years, 81.8% currently
receiving CT). Across this sample, low treatment toxicity was ranked highest (44.6% relative importance, MLR
analysis), followed by ability to self-care (32.3%), and an additional survival benefit of up to 3 months (3 months 23.
1%, 2 months 18.3%, 1 month 11.2%). The MLR analysis showed high validity (certainty 37.9%, chi square p < 0.01,
root-likelihood 0.505). The HB analysis yielded similar results.
Conclusions: Patients’ preferences related to a new hypothetical palliative CT of mGC or mGEJ-Ca can be assessed
by CBCanalysis. Although in real-life, patients initially need to decide on CT before they have any experience, and
patients’ varied experiences with CT will have impacted specific responses, low toxicity and self-care ability were
considered as most important by this group of patients with mGC or mGEJ-Ca.
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Background
In 2012, gastric cancer remained the third most common
cause of cancer death worldwide [1]. Eastern Asia, Eastern
Europe, and South America are areas with a high incidence
[2]. In the United States, 22,220 new cases and 10,990 can-
cer deaths were predicted for 2014 [3]. In Germany, an in-
cidence of approximately 15,000 new cases was predicted
for 2014, and the current 5-year survival rate is 33% [4].
These data include tumors of the gastroesophageal junction
which are becoming increasingly common [5].
At the time of diagnosis, approximately 50% of patients
with gastric cancer already have overt metastatic disease
and are no longer eligible for a curative surgical treatment
approach; chemotherapy (CT) is the mainstay of palliation
and prolonging survival in this setting [5–8]. In older ran-
domized trials evaluating the impact of adding first line
CT to best supportive care, patients’ median overall sur-
vival improved from 3 months to 6 months with a com-
bination of older CT regimens plus best supportive care.
Today, patients would have to choose between a median
life expectancy of 3 months with best supportive care
alone and a median life expectancy of 10–12 months with
a modern CT regimen [7–10].
CT for esophagogastric adenocarcinomas remains
complex with varying standards of care across the world
[2]. CT, with or without addition of targeted therapies, is
considered the standard of care for medically fit patients,
and has been associated with a survival benefit over sup-
portive care only [2]. Treatment decisions concerning
the best approaches to prolong life and preserve or im-
prove quality of life with CT therefore require a careful
trade-off between potential benefits and risks for each
individual patient based on disease characteristics and
comorbidities. However, the weighting of treatment
goals by experts is not necessarily congruent with the
preferences of affected patients [11]. Patients have to
make the decision to have or not to have life-prolonging
palliative CT based on the probabilities derived from re-
search in large populations, with no personal experience
of the potential benefits or toxicities of CT. Further-
more, patients have to decide which regimen/therapeutic
intensity would be most suitable for them. Their deci-
sions are influenced by experiences reported by others
and on information conveyed by their physicians, their
family and friends, the CT nurses, and increasingly from
the internet. Patient preferences in studies are often
assessed after patients have experienced the benefits,
toxicities and outcomes of CT, while the above men-
tioned decisions have to be taken before such experi-
ences were gained.
Patient-reported outcomes and patient preferences have
become increasingly important in the current healthcare
debate [12]. In Germany for example, the “Institut für
Qualität und Wirtschaftlichkeit im Gesundheitswesen”
(IQWiG) is obliged to consider the “patient benefit” as
measured by accepted pharmacoeconomic standards
when evaluating treatment options [13], and states that
this will require a patient preference-based weighting of
relevant endpoints by established methods such as con-
joint analysis [14–16].
Choice-based conjoint (CBC) analysis has indeed be-
come a well-established method to quantify patient pref-
erences [11, 17], and has been applied successfully to
measure preferences for a diverse range of health appli-
cations, including cancer treatments [17]. In contrast to
other common malignancies such as lung or breast can-
cer, however, patient preferences for palliative CT of lo-
cally advanced or metastatic gastric cancer (mGC) have
not been evaluated so far, neither in Germany nor in any
international studies [17]. Due to the specific clinical
situation of these patients, such as their specific prob-
lems associated with food intake, ascites, or maldiges-
tion, patient preferences may differ from those identified
for the treatment of other malignancies on the attribute
level as well as on the weighing of different attributes.
Therefore, we conducted the current study to assess
patient preferences for a new hypothetical palliative CT
of gastric cancer in Germany, using a CBC analysis ap-
proach, in patients with previous or ongoing CT expos-
ure. We interviewed 55 patients with mGC or locally
advanced or metastatic adenocarcinomas of the gastro-
esophageal junction (mGEJ-Ca) who had received at
least 2 cycles of palliative CT in first or later lines of
therapy. The purpose was (1) to evaluate if CBC analysis
can be used appropriately in this type of severely ill can-
cer patients, and (2) to quantify patients’ preferences for
palliative CT when they need to trade-off between differ-
ent attributes while comparing them to direct patients’
treatment goals.
Methods
The study and all interviews were conducted in accordance
with guidelines published by the European Pharmaceutical
Market Research Association (EphMRA) and the European
Society for Opinion and Marketing Research (ESOMAR)
[18, 19]. Hospital- and practice-based oncologists and gas-
troenterologists throughout Germany involved in gastric
cancer treatment were contacted and asked to identify
patients who met the target criteria and were willing to par-
ticipate in the study.
Both qualitative and quantitative interviews were con-
ducted predominantly at the patients’ homes, or at any
location preferred by the patient. Selected moderators
with several years of experience in pharmaceutical and
patient market research conducted the interviews; all pa-
tients had the option to be accompanied by a trusted
person throughout the interview. Both the qualitative
Hofheinz et al. BMC Cancer  (2016) 16:937 Page 2 of 9
and the quantitative surveys were conducted by
MaritzCX, Hamburg, Germany.
Study sample
The target population consisted of adult patients
(≥18 years) with cytologically or histologically confirmed
diagnosis of mGC or mGEJ-Ca who had received at least
2 cycles of palliative CT in first or later lines of therapy.
This CT could either be ongoing or have been com-
pleted within the last 2 years. Patients had to be physic-
ally and mentally capable to participate in a 45-60 min
interview as per opinion of the treating physician.
Patients were recruited by their treating physicians.
Eligible patients received a written patient information
sheet from their physicians which contained the project
description and a response sheet. Patients willing to par-
ticipate were asked to send the response sheet to the re-
search agency, and the interview was then set up.
Qualitative in-depth interviews
Interviewers experienced in quantitative and qualitative
healthcare research projects (MaritzCX, Hamburg,
Germany) conducted 6 initial in-depth interviews. The
interviews were designed to identify those aspects that
patients considered as particularly relevant for palliative
care of their gastric cancer. Patients’ general experience
with the disease, perceived limitations in the daily rou-
tine and in coping with them, perceived benefits and
limitations associated with gastric cancer treatment, and
the patients’ attitudes towards treatment, treatment
needs and treatment goals were addressed.
The interviews were taped, analyzed, and the informa-
tion collected was used to develop the quantitative sur-
vey described below, and to define the attributes and
attribute factor levels for the CBC matrix as outlined
below.
Quantitative interviews
Direct questioning
During the 55 quantitative interviews, a programmed ques-
tionnaire was used by the trained interviewers for data
collection; all data were collected in a pseudonymized for-
mat. Data collected included demographic data and key dis-
ease characteristics, weight loss, and a rating of overall
perceived capabilities. Experience with CT was categorized
as currently receiving or not, but no further details were
collected. In addition, patients’ were directly asked which
treatment goal they considered as most important and what
additional goals they had for the treatment of their mGC
(open-ended questions). Finally, patients were asked to rate
the extent of disease-related limitations regarding their pre-
ferred activities, eating, social activities with friends, family
and partner relationships, and self-care during daily living,
on a Likert scale ranging from 1 (very mild) to 5 (very
strong). In addition, they were asked to name any other
perceived limitations of their activities during daily living
they associated with their disease. The interviewer entered
all responses directly into a tablet or laptop PC during the
interview. No additional patient data were collected from
other sources, e.g. the treating physicians.
Conjoint analysis module
The qualitative in-depth interviews formed the basis for
the development of the CBC analysis matrix that assessed
patient preferences for a new hypothetical palliative CT of
gastric cancer [20]. The matrix spanned 3 attributes in-
cluding “ability to self-care” as a measure for performance
status and quality of life, and “treatment tolerability”, and
“additional survival benefit” as key attributes. These 3 at-
tributes had been identified as most relevant for patients
during the qualitative interviews. In order to keep the
quantitative interviews manageable even for severely ill
participants, the CBC matrix was kept as simple as pos-
sible, with only 3 attributes and 4 different factor levels
each (Table 1), and the number of choice tasks for each
patient (iterations) was limited to 15. The levels were
chosen for each attribute in such a way that the difference
between levels would be reasonable and easily under-
standable for the participants as well as medically sound,
e.g. the additional survival benefit should reflect the differ-
ences seen in median overall survival between older doub-
let and more modern triplet regimens.
Table 1 Attributes and levels used for the choice-based conjoint analysis
Attributes Factor levels
Level 1 Level 2 Level 3 Level 4
1. Ability to self-
care
No assistance required
for activities of daily
living
Little assistance required for
activities of daily living
A lot of assistance required
for activities of daily living
Complete assistance required for
activities of daily living; bed-ridden
2. Treatment
tolerability
(adverse
reactions)
No or mild adverse
reactions possible; no
hospitalization required
Moderate adverse reactions
possible; manageable
without hospitalization
Severe adverse reactions
possible; hospitalization for 3–
4 days may be required
Very severe to life-threatening adverse
reactions possible; hospitalization for
≥5 days may be required
3. Survival benefit
(vs. standard of
care)
No additional survival
benefit
Survival benefit of
approximately 1 additional
month
Survival benefit of
approximately 2 additional
months
Survival benefit of approximately 3
additional months
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During each of the 15 choice tasks, the patient had to
choose which treatment he would prefer among 3 hypo-
thetical treatment profiles with different factor levels for
each of the 3 attributes. The interviewer presented these
hypothetical treatment profiles to the patient on the
screen of a tablet or laptop PC, and then entered the
choices into the tablet or laptop PC on the patient’s
behalf.
Statistical analysis
Sample size
Sample size considerations were based on the standard
formula for sample size estimation for CBC analysis pub-
lished by Johnson and Orme. A minimum sample size of
50 patients was required for the planned CBC design (3
attributes with 4 factor levels each, 15 iterations) [21].
Direct questioning
All data collected by direct questioning (demographic
data, disease characteristics, perceived disease-related lim-
itations, treatment goals) were evaluated descriptively.
Conjoint analysis
Results of the conjoint analysis models were estimated
by a) aggregate multinomial logistic regression (MLR)
[20] and b) hierarchical Bayesian (HB) analysis [20, 22].
MLR modelling mainly describes the preference at the
group level rather than at the individual patient level,
while HB estimation additionally considers patterns at
the individual patient level. The Sawtooth Software
packages SMRT 4.20 and CBC/HB 4.6.4 (Sawtooth Soft-
ware, Inc., Orem, Utah, USA) were used for the MLR
and HB analyses, respectively [20].
The validity of the MLR approach was evaluated based
on the percent certainty (likelihood ratio-index) and chi
square statistics. Both models were evaluated by the root
likelihood. The root likelihood is an intuitive measure of
how well the solution fits the data. The best possible
value is 1.0 (indicating perfect model fit), and the worst
possible value is the reciprocal of the number of choices
available in the average task, i.e. 0.33 in this study (indi-
cating no model fit) [20]. In addition, the validity of both
models was checked by repeating all analyses in 2 sub-
groups derived from a randomly generated 50:50 sample
split. The robustness of the model could be confirmed if
the root likelihood values were similar for the overall
sample and the 2 subgroups.
Estimates of relative importance were calculated for
each factor level (part-worth utilities) and aggregated for
each attribute (total utility). The part-worth utilities were
scaled and normalized in a way that the lowest factor
level for each attribute was assigned a part-worth utility
of 0, and the combination of the best factor levels for all
3 attributes resulted in a total utility of 100. The relative
importance of an individual attribute thus corresponds
to the difference between the highest and the lowest (0)
standardized part-worth utility for that attribute.
Results
Qualitative interviews
The qualitative interviews (N = 6) revealed that patients
with mGC or mGEJ-Ca who had at least some experi-
ence with CT did not evaluate their palliative CT for
gastric cancer based on the survival benefit per se, but
rather on the extent of survival benefit associated with a
high perceived quality of life, which they predominantly
characterized as being able to self-care and receiving a
CT with good tolerability. Therefore, the three aspects
“ability to self-care”, “treatment tolerability” and “sur-
vival benefit” were the key factors used to define the 3
attributes for the CBC matrix (Table 1).
Quantitative phase - direct questioning
A total of 55 additional patients with mGC or mGEJ-Ca
participated in the quantitative survey (face to face inter-
views by trained personnel), 78.2% male, median age
63 years; Table 2). More than 80% of these 55 patients
were receiving CT at the time the interview was con-
ducted (81.8%, Table 2), and the majority felt their per-
ceived capabilities were much worse than before diagnosis
(65.5%). On average, patients perceived disease-related
limitations to be most pronounced for their preferred ac-
tivities (mean index score 3.3, score ranged from 1 [very
weak] to 5 [very strong]), eating (3.1), and social activities
with friends (2.8). Family and partner relationships (2.2)
and self-care during daily living (2.0) were perceived as
less affected. The most common disease-related limita-
tions that the patients specified by additional open-ended
questioning included physical limitations (40.0%), limita-
tions of leisure time activities (30.9%), and physical symp-
toms (21.8%) (Fig. 1a).
When questioned directly, one fourth of the patients
each stated that their most important treatment goal
was to avoid disease progression (25.5%) or to achieve
cure of the disease (25.5%), respectively, followed by im-
proved overall performance (10.9%; Fig. 1b). The most
commonly reported additional treatment goal (multiple
responses possible) was “to experience no limitations in
daily routine” (27.3%). Adding up related treatment goals
showed that improving survival (cure, prolonged sur-
vival, or gaining time) was the most important goal for
54.6% of patients; avoiding disease progression or
achieving tumor shrinkage was most important for
34.6% of patients, while treatment goals related to symp-
tom improvement (improved overall performance, no
limitations in daily routine, and pain-free living) were
most important for 25.5% of patients.
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Conjoint analysis
All 55 patients completed the conjoint analysis; 51
(92.7%) perceived the complete survey, including the
conjoint analysis, as positive or very positive. The 2 dif-
ferent modeling approaches for the data, MLR and HB,
both indicated that the models had high validity (MLR:
certainty 37.9%, chi square p < 0.01, root likelihood
0.505; HB: root likelihood 0.732). In addition, both ana-
lyses gave consistent results, in the overall sample (Figs. 2
and 3) as well as in 2 subgroups generated by a random
50:50 split of the overall sample (data not shown).
Based on both MLR and HB modeling (Fig. 2a and b),
patients considered low treatment toxicity as the most
important preference (relative importance: MLR 44.6%,
HB 46.8%), followed by ability to self-care (MLR 32.3%,
HB 32.1%), and an additional survival benefit of up to
3 months (MLR: 3 months 23.1%, 2 months 18.3%,
1 month 11.2%).
Patients valued a treatment associated with no or mild
adverse reactions only and requiring no hospitalization
twice as important (MLR 1.93fold, HB 2.21fold as im-
portant) as a survival benefit of 3 additional months over
standard of care (relative importance: MLR 44.6% vs.
23.1%, Fig. 3a; HB 46.8% vs. 21.2%, Fig. 3b). Also, they
considered requiring “little assistance for activities of
daily living” 1.4-1.5times as important as a survival bene-
fit of 3 additional months over standard of care (relative
importance: MLR 32.3% vs. 23.1%, Fig. 3a; HB 32.1% vs.
21.2%, Fig. 3b).
Discussion
To our knowledge, this study provides the first patient
preference data for a new hypothetical palliative CT of
gastric cancer, performed after patients had started treat-
ment. All patients were able to complete the CBC mod-
ule, and most (92.7%) perceived the complete survey as
a positive or very positive experience, confirming that
CBC analysis can be appropriately used in these severely
ill patients. In this CBC analysis, treatment tolerability
and the ability to self-care were ranked highest in im-
portance by a sample of 55 patients with mGC or
mGEJ-Ca and varied CT experience over the last 2 years.
A palliative CT associated with no or mild adverse reac-
tions and requiring no hospitalization was considered
twice as important as an additional 3-month survival
benefit, and requiring little or no assistance for daily liv-
ing activities was considered 1.5 times as important as
an additional 3-month survival benefit. The findings in-
dicate that patients with previous CT experience con-
sider a survival benefit accompanied by high quality of
life, i.e. being able to self-care and receiving a treatment
with good tolerability, as more important than an add-
itional survival benefit per se. In direct questioning, the
importance of survival was perceived higher than in the
CBC analysis, yet the weighted responses of patients
trading off between different aspects of their daily life,
disease and treatment in the CBC model provide a
broader picture and should therefore be considered as
more complete when evaluating patient preferences. In
the end, this interpretation is consistent with the results
of the 6 qualitative interviews, and with the results from
direct, open-ended questioning, where goals related to
prolonged survival (prolonged survival, cure, or gaining
time) were most frequently mentioned as the most im-
portant treatment goals, followed by avoiding disease
progression or achieving tumor shrinkage, and treatment
goals related to symptom improvement (improved over-
all performance, no limitations in daily routine, pain-free
living). Nevertheless, physicians should be aware that
Table 2 Baseline characteristics (N = 55)
Characteristic
Age [years]
Median (range) 63 (42–85)
≥ 65 years, n (%) 25 (45.5)
Sex, n (%)
Male 43 (78.2)
Female 12 (21.8)
Relationship, n (%)
Married 39 (70.9)
Single 9 (16.4)
Domestic partnership 5 (9.1)
Widowed 2 (3.6)
Children yes/no 44/11 (80.0/20.0)
Living area, n (%)
Large city (≥100,000 residents) 28 (50.9)
Rural area or small city (<20,000 residents) 15 (27.3)
Medium-sized city (20,000 to <100,000 residents) 12 (21.8)
Current performance, change versus performance before diagnosis, n (%)
Much worse 36 (65.5)
Slightly worse 17 (30.9)
Unchanged 2 (3.6)
Improved 0
Weight loss during the last 6 months, n (%)
Pronounced (>3 kg) 36 (65.5)
Mild (2–3 kg) 8 (14.5)
None 11 (20.0)
Gastric resection, n (%)
Complete resection 18 (32.7)
Partial resection 12 (21.8)
No resection 25 (45.4)
Currently receiving chemotherapy, n (%) 45 (81.8)
n number of patients, N number of patients in study sample
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20.0
10.9
5.5
7.3
7.3
9.1
10.9
12.7
12.7
12.7
21.8
30.9
40.0
0 10 20 30 40 50
No other limitations / areas
Other (single mentions)
Unable to drive a car
Impaired mental performance
Changes in personality / mood swings
Fatigue
No planning latitude (vacations, etc.)
No longer able to do household chores
Social isolation / limitations
Inability to work / limited ability to work
Physical symptoms (circulation, numbness, etc.)
Limitation of leisure time activities
Impaired physical performance
a
b
% patients
25.5
25.5
10.9
9.1
9.1
7.3
5.5
3.6
1.8
1.8
0 5 10 15 20 25 30
No progression ("stop" the disease, maintain the status quo)
Disease cured
Improved overall performance
Not experiencing any limitations in the daily routine
Shrinkage of tumor or metastases
Prolonged survival
Achieve pain-free living
Gaining time
Treatment with no / few adverse reactions
New treatment options offered
% patients
Fig. 1 Direct, open-ended questioning: Summary of perceived disease-related limitations (Panel a) and treatment goals (Panel b) (N= 55). a. Perceived
disease-related limitations (open-ended question, multiple responses possible). b. Most important treatment goals (single responses only). Abbreviations: N,
number of patients in the study sample
46.8
32.1
21.2
44.6
32.3
23.1
Treatment tolerability
Ability to self-care
Survival benefit (vs.
standard of care)
Mixed logit regression Hierarchical Bayes analysis
Fig. 2 Conjoint Analysis: Relative importance of the 3 attributes (N = 55), analyzed by multinomial logistic regression (MLR, left pie) and hierarchical
Bayesian analysis (HB, right pie)
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they need to word their questions carefully when trying
to identify their patients’ true preferences. Patient prefer-
ences may have differed depending on patients’ main
treatment goals. However, the sample size (N = 55) pre-
cluded any subgroup analysis by treatment goal.
Patient preferences have been previously evaluated for
other tumor entities such as breast cancer or non-small
cell lung cancer (NSCLC) [23, 24]. These studies indi-
cate that preferences may differ considerably, depending
on factors such as tumor type, severity of disease, and
44.6
33.3
11.8
0
No or mild ARs possible; no hospitalization required
a
b
Moderate ARs possible; manageable without hospitalization
Severe ARs possible; hospitalization for 3-4 days
may be required
Very serious to life-threatening ARs possible; 
hospitalization for ≥5 days may be required
32.3
31.2
15.2
0
Little assistance required for activities of daily living
No assistance required for activities of daily living
A lot of assistance required for activities of daily living
Full assistance required for activities of daily living;
bed-ridden
23.1
18.3
11.2
0
0 10 20 30 40 50
Survival benefit of approx. 3 additional months
Survival benefit of approx. 2 additional months
Survival benefit of approx. 1 additional month
No additional survival benefit
%
Ability to self-care 
Survival benefit  (vs. standard of care)
32.1
31.8
15.5
0
Little assistance required for activities of daily living
No assistance required for activities of daily living
A lot of assistance required for activities of daily living
Full assistance required for activities of daily living;
bed-ridden
46.8
36.5
16.1
0
No or mild ARs possible; no hospitalization required
Moderate ARs possible; manageable without
hospitalization
Severe ARs possible; hospitalization for 3-4 days
may be required
Very serious to life-threatening ARs possible; 
hospitalization for ≥5 days may be required
21.2
16.5
11.2
0
0 10 20 30 40 50
Survival benefit of approx. 3 additional months
Survival benefit of approx. 2 additional months
Survival benefit of approx. 1 additional month
No additional survival benefit
Ability to self-care
Survival benefit (vs. standard of care)
%
Fig. 3 Conjoint analysis: Relative importance of the individual factor levels (N = 55), analyzed by multinomial logistic regression (MLR, panel a) and
hierarchical Bayesian analysis (HB, panel b). a Multinomial logistic regression analysis. b Hierarchical Bayesian analysis. Abbreviations: approx.,
approximately; AR, adverse reactions; N, number of patients in study sample
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extent of previous treatment. For example, a CBC study
in 121 patients with Stage I-IV breast cancer, all treated
with CT during the last 5 years, identified a survival
benefit of 3 months as the most important preference.
These patients considered a more convenient adminis-
tration regimen as less important than a 13% chance or
more of severe toxicities, but more important than a
10–12% chance of severe toxicities [23]. In another re-
cent study, 211 patients with NSCLC who had been
treated within the last 2 years considered an increase in
progression-free survival as the most important factor,
followed by a reduction in tumor-associated symptoms
(cough, shortness of breath, and pain), and the reduction
of side effects. Mode of administration was considered
as least important.
Subgroup analyses revealed that the relative import-
ance of “progression-free survival” increased with ther-
apy experience [24].
In all these previous investigations, as well as the
current study, patients were already exposed to CT be-
fore patient preferences were assessed. In this study,
more than 80% of patients were currently receiving CT
when they completed the survey. This limits the inform-
ative value for the strategic decision for or against CT
based on median survival data from randomized clinical
trials as patients still do not have any experience of the
potential benefits and toxicities. Yet, the results give
hints for patients’ preferences when choosing between
different treatment options. Also, patients who have pre-
viously experienced a palliative benefit (e.g. improved
dysphagia) or tumor response can be expected to be
more in favor of CT than patients who had progressive
disease and experienced adverse reactions. In addition,
untreated, less severely ill patients might consider ad-
verse reactions as less important and survival benefit as
more important than patients currently suffering from
adverse reactions during CT. Because performance sta-
tus, the treatment regimen given, the timing of the sur-
vey in relation to patients’ ongoing CT (i.e. during
recovery period between cycles or during acute toxicity
phase), tumor response, and toxicity data were not cap-
tured in this survey, their impact on patient preferences
could not be assessed. This might be considered as con-
siderable limitation. On the other hand, including differ-
ent patients with different CT experiences may help to
mirror the real-life situation more closely. Further, the
study included only patients who were willing to partici-
pate and were considered fit enough for participation by
their physician. Therefore, the study population may not
be representative of the general population of gastric
cancer patients receiving palliative CT.
Another limitation of the study is that while the max-
imum additional survival benefit over standard of care in
the fictive patient profiles of the conjoint analysis survey
was 3 months which reflects the differences between
various modern CT regimens (older vs. more modern,
doublet vs. triplet), modern first-line CT regimens offer
a more pronounced survival benefit of up to 9 months
over best supportive care [7–10]. Finally, the sample size
was limited in our study, and it cannot be excluded that
the recruitment procedure (treating physicians contacted
target patients) may have resulted in selection bias. On
the other hand, the high root likelihood values for both
models (MLR and HB) and the consistency of results
across different model approaches indicate that the CBC
analysis provided high-validity results.
Conclusions
Patient preferences related to a hypothetical new pallia-
tive CT of gastric cancer can be assessed by CBC ana-
lysis performed after patients have gained at least some
experience of their own toxicity profile and the effect of
CT on their cancer. Though patients’ varied experiences
with CT will have impacted specific responses, across
this sample of patients with esophagogastric adenocar-
cinoma, low toxicity and self-care ability were ranked
highest in importance. These preferences of patients
already under CT might not reflect the actual prefer-
ences of all patients with mGC and mGEJ-Ca, but may
nevertheless help to guide the strategic decision between
different CT regimens of so far untreated patients, as
well as those faced with the decision about subsequent
therapy. Future studies will have to validate this ap-
proach by gaining more detailed and real-world evi-
dence, i.e. by evaluating patient preferences before and
during CT exposure in a longitudinal study, considering
the impact of tumor response on patient preferences.
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